GlobeNewswire

In-Memory Computing Summit Previews Agenda for Second Annual European Conference

Dela

Register by April 22, 2018 to Receive a 30 Percent Discount

 

FOSTER CITY, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- GridGain Systems, provider of enterprise-grade in-memory computing platform solutions based on Apache® Ignite(TM), today offered a preview of breakout sessions for the second annual In-Memory Computing Summit® Europe, the premier In-Memory Computing (IMC) conference for computing experts from across Europe and Asia. The announced breakout session speakers include representatives from Arenadata, GridGain Systems, Incedo, Intel, Neeve Research, Nomad Tech, ScaleOut Software, The Glue and VoltDB. The IMC Summit Europe will take place at the Park Plaza Victoria London, June 25-26, 2018. Attendees can receive a 30 percent Super Saver discount on the registration fee by registering by April 22, 2018. Sponsorship opportunities are available for companies that want to reach the IMC Summit's unique audience.

The In-Memory Computing Summit Europe 2018 is the only in-memory computing conference focusing on the full range of in-memory computing-related technologies and solutions. Attendees will learn about the role of in-memory computing in the digital transformation of enterprises. The conference is attended by technical decision makers, business decision makers, architects, CTOs, developers and more who make or influence purchasing decisions about in-memory computing, Big Data, Fast Data, IoT and HPC solutions.

Breakout sessions for the event will include:

  • How to Build an Event-Driven, Dynamically Re-Configurable Micro-Services Platform - Sven Beauprez, Lead Architect, The Glue
  • How to Identify the Most Appropriate In-Memory Database Solution for Computing and Application Requirements - Chitij Chauhan, Subject Matter Expert, Distributed Databases, Incedo
  • When One Minute Can Cost You a Million: Predicting Share Prices in Real-Time with Apache Spark and Apache Ignite - Manuel Mourato, Big Data Engineer, Nomad Tech
  • Apache Ignite as MPP Accelerator - Alexander Ermakov, Chief Technology Officer, Arenadata
  • Intel Memory Drive Technology (IMDT) - Ravikanth Durgavajhala, SSD Solutions Architect, Intel Corporation
  • Integrating Data-Parallel Analytics into Stream-Processing Using an In-Memory Data Grid - William Bain, CEO, ScaleOut Software, Inc.
  • Real-Time with Artificial Intelligence: The Convergence of Big Data and Artificial Intelligence - Colin MacNaughton, Head of Engineering, Neeve Research
  • Ways to Recover In-Memory Data on a Disaster - Alparslan Avci, Solutions Architect, Hazelcast
  • Things You Learn as You Massively Scale - David Rolfe, Director of Solutions Engineering, VoltDB Inc.
  • Designing Multi-Cluster Applications - Lucas Beeler, Senior Consultant, GridGain Systems

Super Saver Registration Discounts
Attendees can receive a 30 percent discount versus the full price General Admission rate by registering early. The Super Saver rate of €375 ends on April 22, 2018. Register via the conference website, or email attendance and registration questions to info@imcsummit.org.

Sponsorships 
By sponsoring the In-Memory Computing Summit Europe, organizations gain a unique opportunity to enhance their visibility and reputation as leaders in in-memory computing products and services. They can interact with key in-memory computing business and technical decision makers, connect with technology purchasers and influencers, and help shape the future of Fast Data. Platinum, Gold and Silver sponsorship packages are currently available. Current sponsors include GridGain Systems, ScaleOut Software, Data Centre Solutions, Digitalisation World, Enterprise Times, IT for CEOs and CFOs, IT Pro.

About the In-Memory Computing Summit
The In-Memory Computing Summits in Europe and North America are the only industry-wide events tailored to in-memory computing-related technologies and solutions. They are the perfect opportunity to connect with technical IT decision makers, IT implementers, and developers who make or influence purchasing decisions in the areas of in-memory computing, Big Data, Fast Data, IoT and HPC. Attendees include CEOs, CIOs, CTOs, VPs, IT directors, IT managers, data scientists, senior engineers, senior developers, architects and more. The Summits are unique forums for networking, education and the exchange of ideas - ideas that power the new world and future of Fast Data. For more information, visit https://imcsummit.org and follow the event on Twitter @IMCSummit.

About GridGain® Systems
GridGain Systems is revolutionizing real-time data access and processing by offering an in-memory computing platform built on Apache® Ignite(TM). GridGain solutions are used by global enterprises in financial, software, e-commerce, retail, online business services, healthcare, telecom and other major sectors, with a client list that includes Barclays, ING, Sberbank, Finastra, IHS Markit, Workday, and Huawei. GridGain delivers unprecedented speed and massive scalability to both legacy and greenfield applications. Deployed on a distributed cluster of commodity servers, GridGain software can reside between the application and data layers (RDBMS, NoSQL and Apache® Hadoop®), requiring no rip-and-replace of the existing databases, or it can be deployed as an in-memory transactional SQL database. GridGain is the most comprehensive in-memory computing platform for high-volume ACID transactions, real-time analytics, web-scale applications, continuous learning and HTAP. For more information, visit gridgain.com.

CONTACT:
Terry Erisman
GridGain Systems
terisman@gridgain.com
(650) 241-2281

GridGain and the In-Memory Computing Summit are trademarks or registered trademark of GridGain Systems, Inc. Apache, Apache Hadoop, Hadoop, Apache Ignite, and Ignite are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: GridGain Systems via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum